Wednesday 19 December 2012

Africa Fighting Malaria Updates and Events


Africa Fighting Malaria (AFM) seeks to raise awareness of the huge burden of malaria in sub-Saharan Africa and promote sensible policies for long-term solutions.
 
Most donor agencies only procure drugs approved by a Stringent Regulatory Authority or the World Health Organization (WHO) Prequalification Programme in an effort to ensure high quality. However, the US President's Malaria Initiative has occasionally had to return approved drugs with quality issues to the manufacturer. This study compares the quality of artemisinin-based combination therapies (ACTs) produced by WHO-approved manufacturers with non-approved manufacturers and suggests policy changes to improve quality of donor-procured drugs. 
  
Other News
Events and Information
Scaling up malaria treatment: a review of the performance of different providers

Despite great progress towards malaria control, the disease continues to be a major public health problem in many developing countries, especially for poor women and children in remote areas. Resistance to artemisinin combination therapy (ACT) emerged in East Asia. Its spread would threaten the only effective malaria treatment currently available. Improvement in availability of diagnosis as part of malaria control has highlighted the fact that many fevers are not due to malaria. These fevers also need to be promptly diagnosed and adequately treated in order to improve public health outcomes in developing countries. 

Regardless of the growing interest in detecting population structures in malarial parasites, there have been limited discussions on how to use this concept in control programmes. In such context, the effects of the parasite population structures will depend on interventions' spatial or temporal scales.
Read More 
Also on FightingMalaria.org

Please email Africa@fightingmalaria.orgfor more information.

No comments:

Post a Comment